JP2025026572A5 - - Google Patents

Download PDF

Info

Publication number
JP2025026572A5
JP2025026572A5 JP2024213235A JP2024213235A JP2025026572A5 JP 2025026572 A5 JP2025026572 A5 JP 2025026572A5 JP 2024213235 A JP2024213235 A JP 2024213235A JP 2024213235 A JP2024213235 A JP 2024213235A JP 2025026572 A5 JP2025026572 A5 JP 2025026572A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
pharmaceutical composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024213235A
Other languages
English (en)
Japanese (ja)
Other versions
JP7788118B2 (ja
JP2025026572A (ja
Filing date
Publication date
Priority claimed from PCT/IL2020/050047 external-priority patent/WO2020144697A1/en
Application filed filed Critical
Publication of JP2025026572A publication Critical patent/JP2025026572A/ja
Publication of JP2025026572A5 publication Critical patent/JP2025026572A5/ja
Application granted granted Critical
Publication of JP7788118B2 publication Critical patent/JP7788118B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024213235A 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体 Active JP7788118B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962791808P 2019-01-13 2019-01-13
US62/791,808 2019-01-13
PCT/IL2020/050047 WO2020144697A1 (en) 2019-01-13 2020-01-13 Antibodies specific to human nectin-2
JP2021539922A JP7606706B2 (ja) 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021539922A Division JP7606706B2 (ja) 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体

Publications (3)

Publication Number Publication Date
JP2025026572A JP2025026572A (ja) 2025-02-21
JP2025026572A5 true JP2025026572A5 (https=) 2025-03-13
JP7788118B2 JP7788118B2 (ja) 2025-12-18

Family

ID=69701225

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539922A Active JP7606706B2 (ja) 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体
JP2024213235A Active JP7788118B2 (ja) 2019-01-13 2024-12-06 ヒトネクチン-2に特異的な抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021539922A Active JP7606706B2 (ja) 2019-01-13 2020-01-13 ヒトネクチン-2に特異的な抗体

Country Status (9)

Country Link
US (2) US12545727B2 (https=)
EP (1) EP3908372A1 (https=)
JP (2) JP7606706B2 (https=)
KR (1) KR20210117277A (https=)
CN (2) CN118878685A (https=)
AU (1) AU2020207664B2 (https=)
CA (1) CA3125962A1 (https=)
IL (1) IL284807B2 (https=)
WO (1) WO2020144697A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240152879A (ko) 2022-02-28 2024-10-22 넥틴 테라퓨틱스 리미티드 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
EP4716696A1 (en) 2023-05-23 2026-04-01 Fondazione Per L'Istituto Oncologico Di Ricerca (IOR) Monospecific and bispecific antibodies and antibody-drug conjugates targeting nectin2 (cd112) and psma
WO2024240899A1 (en) 2023-05-23 2024-11-28 Universite De Geneve Dual targeting of psma and nectin2 in prostate cancer
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
KR20250161706A9 (ko) * 2024-05-08 2026-02-03 아주대학교산학협력단 Nectin-2에 특이적으로 결합하는 항체 및 이의 용도
KR20250161707A (ko) * 2024-05-08 2025-11-18 아주대학교산학협력단 Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도
KR20250175021A (ko) 2024-06-05 2025-12-16 아주대학교산학협력단 Nectin-2에 특이적으로 결합하는 인간화 항체 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20090142346A1 (en) 2005-10-07 2009-06-04 Takeda Pharmaceutical Company Limited Preventive/Remedy for Cancer
JPWO2008044754A1 (ja) * 2006-10-06 2010-02-18 武田薬品工業株式会社 癌の予防・治療剤
WO2008126847A1 (ja) 2007-04-11 2008-10-23 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
CN104011925A (zh) 2011-12-27 2014-08-27 株式会社Lg化学 锂二次电池及其制备方法
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3344658B1 (en) * 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
US10407484B2 (en) 2015-09-02 2019-09-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
CN108513576A (zh) 2015-09-14 2018-09-07 高山免疫科学股份有限公司 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
US20190224339A1 (en) 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
LT3535392T (lt) * 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
KR20240152879A (ko) 2022-02-28 2024-10-22 넥틴 테라퓨틱스 리미티드 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체

Similar Documents

Publication Publication Date Title
JP2025026572A5 (https=)
JP6953612B2 (ja) チェックポイントインヒビター二重特異性抗体
JP2022050618A5 (https=)
JP2021501162A5 (https=)
JP2020508317A5 (https=)
JP2019515008A5 (https=)
JP2022532490A5 (https=)
JP2021510736A5 (https=)
JP2020527332A5 (https=)
JP2025183307A5 (https=)
JP2022519341A5 (https=)
JP2021512107A5 (https=)
JP2023155262A (ja) プレクチン1結合抗体およびその使用
JP2023548051A5 (https=)
US11110179B2 (en) Combination of CD33 antibody drug conjugates with chemotherapeutic agents
AU2022364154A1 (en) Subcutaneous administration of cd19-binding t cell engaging antibodies
JP2022548212A (ja) マルチチロシンキナーゼ阻害剤及び免疫チェックポイント阻害剤を含む組合せを用いた癌の治療
WO2017180768A1 (en) Combinations of cd33 antibody drug conjugates with hypomethylating agents
JP2023546293A5 (https=)
WO2025082449A1 (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
AU2018347406B2 (en) Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
CN112955148A (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
CN117693350A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
JP2020507569A5 (https=)
JP2022535276A5 (https=)